Kite Pharma and Experimental Transplantation and Immunology Branch (ETIB) of National cancer Institute (NCI ) have entered a co-operative research and development (R&D) agreement (CRADA) to develop T-cell receptor (TCR) product candidates for the treatment of HPV associated cancers.
Pursuant to the agreement, NCI will develop separately designed TCR therapy candidates targeting HPV-16 E6 oncoprotein and will research on novel TCR therapy candidates targeting HPV-10 E7 oncoprotein.
The partnership enables Kite Pharma and National Cancer Institute (NCI) to advance the research and clinically development of T-cell receptor product candidates against human papillomavirus (HPV)-16 E6 and E7 oncoproteins to treat HPV associated cancers.
Waters Corporation has entered a co-development agreement with Bioprocessing Technology Institute (BTI ) to develop new techniques to identify cancer markers and probe cancer biology.
According to the agreement, both partners will jointly elucidate new therapeutic strategies through glycosylation pathways and develop a glycosphingolipid (GSL) head group database with glucose retention times and collision cross section values. Waters will contribute scientific expertise by using its proprietary, SYNAPT G2-S, high-definition, mass spectrometry system.
Retrophin Inc. has entered a definitive agreement with Asklepion Pharmaceuticals to acquire the rights, titles and ownership of a liquid formulation of ursodeoxycholic acid, which enables it to develop and commercialise a drug candidate for the treatment of primary biliary cholangitis (PBC).
According to the agreement, Retrophin has paid $0.5m upfront to Asklepion Pharma and will also pay up to $23.5m based on sales milestones and incremental milestone payments of up to $35m, upon successful development and commercialisation of the liquid formulation of ursodeoxycholic acid.
ST Pharm Co. Ltd has announced they will raise gross proceeds of $113.6m through the initial public offering (IPO) of its 4,664,000 shares.
The company plans to invest the raised funds for financing facilities and increasing the working capital.
Pharmaceutical company Shanxi C&Y Pharmaceutical Group plans to acquire Shanxi Powerdone Pharmaceutics through the funds raised from private placement of its shares.
The company expects to raise gross proceeds of up to $472.36m from the placement.
